抗幽门螺杆菌对腹型过敏性紫癜疗效的研究

The curative effect of anti-helicobacter pylocri treatment on Henock-Schonlein purpura

目的探讨抗幽门螺旋杆菌(HP)治疗对腹型过敏性紫癜(HSP)预后的影响。方法 90例有消化道症状且非侵入性尿素[14C]呼气试验检测HP呈阳性的HSP患者,随机分成二组,分别接受常规治疗(对照组)和常规加抗HP治疗(治疗组),比较两组疗效及复发率。结果 45例对照组痊愈18例,有效15例,无效12例,复发18例,45例治疗组痊愈39例,有效6例,无复发病例。两组有效率和复发率比较均有显著差异性(P<0.01 u=4>2.58,P<0.01 u=5.47>2.58)。结论 HP感染与HSP预后密切相关。HP感染不仅是HSP病因之一,且消除HP可较快缓解胃肠道症状提高治疗有效率,减少复发。故对有HP感染的HSP患者应在常规治疗的同时加上抗HP三联治疗。

Objective The impact of anti-Helicobacter pylori （HP） treatment on the prognosis of Henoch-Schonlein purpura （HSP） was investigated. Methods 90 patients with SHP, which was combined with gastrointestinal symptoms and positive HP detection by urea non-invasive [ 14C] breath test, were randomly divided into two groups. The patients were treated with conventional therapy （control group） or conventional therapy plus anti-HP therapy （treatment group）. The curative effect and recurrence rate of patients in the two groups were compared. Results Of 45 cases in control group, 18 cases were cured and 18 cases were recurred. 39 cases were cured and no case recurred in treatment group. The curative effect and recurrence rate were significantly different between the two groups （P〈0. 01 ）. Conclusion HP infection was correlated with the prognosis of HSP. HP infection wa an important pathogen of HSP. Moreover, anti -HP therapy was helpful to alleviate the gastrointestinal symptoms, improve the curative effect and reduce the recurrent rate.